|
MIER3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.65778543407214E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.49620016165875E-10 |
| Normal-vs-Stage2 |
1.980020E-04 |
| Normal-vs-Stage3 |
2.33099983759644E-10 |
| Normal-vs-Stage4 |
4.08779676774884E-11 |
| Stage1-vs-Stage2 |
6.086800E-01 |
| Stage1-vs-Stage3 |
5.407800E-02 |
| Stage1-vs-Stage4 |
1.724960E-03 |
| Stage2-vs-Stage3 |
1.034390E-01 |
| Stage2-vs-Stage4 |
1.648090E-02 |
| Stage3-vs-Stage4 |
2.186800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.39519507058594E-11 |
| Normal-vs-AfricanAmerican |
7.020700E-04 |
| Normal-vs-Asian |
1.77680000046365E-07 |
| Caucasian-vs-AfricanAmerican |
5.940800E-01 |
| Caucasian-vs-Asian |
9.375000E-01 |
| AfricanAmerican-vs-Asian |
5.827000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6587999862594E-09 |
| Normal-vs-Female |
3.13959969133748E-11 |
| Male-vs-Female |
9.239600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.09679998416823E-09 |
| Normal-vs-Age(41-60Yrs) |
7.5716999337061E-10 |
| Normal-vs-Age(61-80Yrs) |
5.44930001122879E-09 |
| Normal-vs-Age(81-100Yrs) |
1.751940E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.167200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.798600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.650800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.191800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.768600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.764800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.046900E-04 |
| Classical-VS-Follicular |
6.240200E-01 |
| Classical-VS-Other |
6.082000E-01 |
| Classical-VS-Normal |
1.07620001799091E-09 |
| Tall-VS-Follicular |
6.223700E-03 |
| Tall-VS-Other |
2.523000E-01 |
| Tall-VS-Normal |
9.61160040446885E-11 |
| Follicular-VS-Other |
7.626400E-01 |
| Follicular-VS-Normal |
5.91139999950308E-07 |
| Other-VS-Normal |
1.290490E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.40889996838689E-09 |
| Normal-vs-N1 |
1.55610000440731E-08 |
| N0-vs-N1 |
4.102200E-01 |
|
|
